Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (40.4), the stock would be worth ¥73.27 (30% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 31.2 | ¥56.56 |
0%
|
| 3-Year Average | 40.4 | ¥73.27 |
+30%
|
| 5-Year Average | 60.5 | ¥109.52 |
+94%
|
| Industry Average | 26.2 | ¥47.48 |
-16%
|
| Country Average | 28.8 | ¥52.22 |
-8%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
¥3.6B
|
/ |
Oct 2025
¥112.5m
|
= |
|
|
¥3.6B
|
/ |
Dec 2025
¥160.6m
|
= |
|
|
¥3.6B
|
/ |
Dec 2026
¥202m
|
= |
|
|
¥3.6B
|
/ |
Dec 2027
¥261.6m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Medprin Regenerative Medical Technologies Co Ltd
SZSE:301033
|
3.8B CNY | 31.2 | 37 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 45.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 13.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 18.9 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 24.9 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 30.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 9.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.3 |
| Median | 28.8 |
| 70th Percentile | 53.1 |
| Max | 49 021 |
Other Multiples
Medprin Regenerative Medical Technologies Co Ltd
Glance View
Medprin Regenerative Medical Technologies Co. Ltd. engages in the development of implanted medical devices. The company is headquartered in Guangzhou, Guangdong and currently employs 271 full-time employees. The company went IPO on 2021-07-26. The firm's implanted medical device products include artificial dura mater (spine) patch, cranio-maxillofacial repair products and absorbable hemostatic yarns. 3D printing equipment includes biological 3D printers, resin 3D printers and other related supporting components. Technical services include general technical services and scientific research services. The firm distributes its products both in the domestic market and to overseas markets.
